Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. The Outsourcing Facilities Association and a Texas-based compounder have filed a lawsuit against the FDA in U.S. District Court in Fort Worth for declaring the shortage over for Novo's semaglutide.
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. The Outsourcing Facilities Association and a Texas-based compounder have filed a lawsuit against the FDA in U.S. District Court in Fort Worth for declaring the shortage over for Novo's semaglutide.
